

**THIS IS A \*REVISED FILE**  
**\*REVISED FILES REQUIRE A "DISPOSITION APPROVAL" SIGNATURE. VariMed CAN NOT RELEASE THE "APPROVED" "REVISED" ART WITH OUT THIS SIGNATURE.**

**OVERDOSAGE**  
The most common manifestation of hydroxyzine overdosage is hypersedation. As in the management of overdosage with any drug, it should be borne in mind that multiple agents may have been taken.

If vomiting has not occurred spontaneously, it should be induced. Immediate gastric lavage is also recommended. General supportive care, including frequent monitoring of the vital signs and close observation of the patient, is indicated. Hypotension, though unlikely, may be controlled with intravenous fluids and levarterenol, or metaraminol. Do not use epinephrine as hydroxyzine counteracts its pressor action.

There is no specific antidote. It is doubtful that hemodialysis would be of any value in the treatment of overdosage with hydroxyzine. However, if other agents such as barbiturates have been ingested concomitantly, hemodialysis may be indicated. There is no practical method to quantitate hydroxyzine in body fluids or tissue after its ingestion or administration.

**DOSAGE AND ADMINISTRATION**  
For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested: in adults, 50 to 100 mg q.i.d.; children under 6 years, 50 mg daily in divided doses and over 6 years, 50 to 100 mg daily in divided doses.

For use in the management of pruritus due to allergic conditions such as chronic urticaria and

atopic and contact dermatoses, and in histamine-mediated pruritus: in adults, 25 mg t.i.d. or q.i.d.; children under 6 years, 50 mg daily in divided doses and over 6 years, 50 to 100 mg daily in divided doses.

As a sedative when used as a premedication and following general anesthesia: 50 to 100 mg in adults, and 0.6 mg/kg in children.

When treatment is initiated by the intramuscular route of administration, subsequent doses may be administered orally.

As with all medications, the dosage should be adjusted according to the patient's response to therapy.

**HOW SUPPLIED**  
Hydroxyzine Hydrochloride Syrup, USP 10 mg per 5 mL (teaspoonful) is a colorless, peppermint-flavored syrup, supplied in 4 fl oz (118 mL) and Pint (473 mL) bottles.

**RECOMMENDED STORAGE**  
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

**PROTECT FROM FREEZING**  
**PROTECT FROM LIGHT**  
Dispense in a tight, light-resistant container as defined in the USP, with child-resistant closure.  
**Rx Only**

Product No.: 8150  
**Manufactured For: Wockhardt USA, LLC.**  
 Parsippany, NJ 07054  
**Manufactured By: Morton Grove Pharmaceuticals, Inc.**  
 Morton Grove, IL 60053  
 A50-8150-04  
 REV. 04-14

This page intentionally left blank

Each 5 mL (teaspoonful) contains:  
 Hydroxyzine Hydrochloride, USP ..... 10 mg  
 Alcohol ..... 0.5%  
 Slight loss unavoidable

**USUAL DOSAGE:** See package insert.  
**WARNINGS:** KEEP OUT OF REACH OF CHILDREN. In case of accidental overdose, seek professional assistance or contact a Poison Control Center immediately.  
**RECOMMENDED STORAGE:** Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].  
**PROTECT FROM LIGHT**  
 Dispense in a tight, light-resistant container as defined in the USP, with child-resistant closure.  
 Manufactured by: Wockhardt USA, LLC.  
 Parsippany, NJ 07054  
 Manufactured By: Morton Grove Pharmaceuticals, Inc.  
 Morton Grove, IL 60053

**MGP**  
 NDC 60432-150-04  
**HydroXYzine**  
**HYDROCHLORIDE**  
**SYRUP, USP**  
**10 mg/5 mL**  
 Alcohol 0.5%  
 DO NOT USE IF INNER FOIL SEAL PRINTED  
 "SEALED FOR YOUR PROTECTION"  
 IS BROKEN OR MISSING.  
**Rx Only**  
**NET: 4 fl oz (118 mL)**

**HYDROXYZINE HYDROCHLORIDE SYRUP, USP**  
 10 mg/5 mL  
 Rx only

**DESCRIPTION**  
 Hydroxyzine hydrochloride is designated chemically as (±)-2-[2-[4-(p-Chloro-α-phenylbenzyl)-1-piperazinyl]ethoxy]ethanol dihydrochloride. Its structural formula is as follows:

$C_{21}H_{27}ClN_2O_2 \cdot 2HCl$  M.W. 447.83

**Inactive Ingredients** for Hydroxyzine Hydrochloride Syrup are: alcohol 0.5%; liquid sugar; methylparaben; peppermint oil; propylene glycol; propylparaben; purified water and spearmint oil. **It may also contain** citric acid anhydrous or sodium citrate dihydrate for pH adjustment. The pH range is between 2.0 and 4.3.

**CLINICAL PHARMACOLOGY**  
 Hydroxyzine hydrochloride is unrelated chemically to the phenothiazines, reserpine, meprobamate, or the benzodiazepines.

Hydroxyzine is not a cortical depressant, but its action may be due to a suppression of activity in certain key regions of the subcortical area of the central nervous system. Primary skeletal muscle relaxation has been demonstrated experimentally. Bronchodilator activity, and antihistaminic and analgesic effects have been demonstrated experimentally and confirmed clinically. An antiemetic effect, both by the apomorphine test and the veroid test, has been demonstrated. Pharmacological and clinical studies indicate that hydroxyzine in therapeutic dosage does not increase gastric secretion or acidity and in most cases has mild antisecretory activity. Hydroxyzine is rapidly absorbed from the gastrointestinal tract and its clinical effects are usually noted within 15 to 30 minutes after oral administration.

**INDICATIONS AND USAGE**  
 For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested.

Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus.

As a sedative when used as premedication and following general anesthesia, **hydroxyzine may potentiate meperidine and barbiturates**, so their use in pre-anesthetic adjunctive

therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitals in any way and it may be used concurrently with this agent.

The effectiveness of hydroxyzine as an anti-anxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient.

**CONTRAINDICATIONS**  
 Oral hydroxyzine hydrochloride is contraindicated in patients with known hypersensitivity to hydroxyzine hydrochloride products, and in patients with known hypersensitivity to cetirizine hydrochloride or levocetirizine hydrochloride.

Hydroxyzine, when administered to the pregnant mouse, rat, and rabbit, induced fetal abnormalities in the rat and mouse at doses substantially above the human therapeutic range. Clinical data in human beings are inadequate to establish safety in early pregnancy. Until such data are available, hydroxyzine is contraindicated in early pregnancy.

Hydroxyzine is contraindicated for patients who have shown a previous hypersensitivity to it.

**WARNINGS**  
**Keep out of the reach of children.**  
**Nursing Mothers:** It is not known whether this drug is excreted in human milk. Since many

drugs are so excreted, hydroxyzine should not be given to nursing mothers.

**PRECAUTIONS**  
 THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES. Therefore, when central nervous system depressants are administered concomitantly with hydroxyzine, their dosage should be reduced.

Since drowsiness may occur with use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery while taking hydroxyzine. Patients should be advised against the simultaneous use of other CNS depressant drugs, and cautioned that the effect of alcohol may be increased.

**Geriatric Use:** A determination has not been made whether controlled clinical studies of hydroxyzine included sufficient numbers of subjects aged 65 and over to define a difference in response from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.

The extent of renal excretion of hydroxyzine has not been determined. Because elderly

patients are more likely to have decreased renal function, care should be taken in dose selections.

Sedating drugs may cause confusion and oversedation in the elderly; elderly patients generally should be started on low doses of hydroxyzine and observed closely.

**ADVERSE REACTIONS**  
 Side effects reported with the administration of hydroxyzine hydrochloride are usually mild and transitory in nature.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Wockhardt USA, LLC at 1-800-445-4290

**Skin and Appendages:** Oral hydroxyzine is associated with fixed drug eruptions in postmarketing reports.

**Anticholinergic:** Dry mouth.

**Central Nervous System:** Drowsiness is usually transitory and may disappear in a few days of continued therapy or upon reduction of the dose. Involuntary motor activity including rare instances of tremor and convulsions have been reported, usually with doses considerably higher than those recommended. Clinically significant respiratory depression has not been reported at recommended doses.

**MGP PROOFING**

Signature 1 \_\_\_\_\_ Date \_\_\_\_\_  
 Signature 2 \_\_\_\_\_ Date \_\_\_\_\_

MAKE CHANGES; SEND NEW PROOFS

---

OK TO PRINT  
 APPROVED BY \_\_\_\_\_  
(Signature Required)

This color proof or PDF is a representation of the colors and will not reflect the final press output.

**DISPOSITION**


It is important that OLD computer files/disks, art, plates and negs be destroyed to avoid production of obsolete items. Please approve the above procedure when approving the revised art.

**DISPOSITION APPROVED BY** \_\_\_\_\_

**DATE** \_\_\_\_\_

# THIS IS A \*REVISED FILE

\*REVISED FILES REQUIRE A "DISPOSITION APPROVAL" SIGNATURE. VariMed CAN NOT RELEASE THE "APPROVED" "REVISED" ART WITH OUT THIS SIGNATURE.



<b>MGP PROOFING</b>	
Signature 1 _____	Date _____
Signature 2 _____	Date _____
<input type="checkbox"/> MAKE CHANGES; SEND NEW PROOFS	
<input type="checkbox"/> OK TO PRINT APPROVED BY _____ <small>(Signature Required)</small>	



This color proof or PDF is a representation of the colors and will not reflect the final press output.

## DISPOSITION

It is important that OLD computer files/disks, art, plates and negs be destroyed to avoid production of obsolete items. Please approve the above procedure when approving the revised art.

DISPOSITION APPROVED BY \_\_\_\_\_

DATE \_\_\_\_\_

**THIS IS A \*REVISED FILE**  
**\*REVISED FILES REQUIRE A “DISPOSITION APPROVAL” SIGNATURE. VariMed CAN NOT RELEASE THE “APPROVED”**  
**“REVISED” ART WITH OUT THIS SIGNATURE.**


 <p>NDC 60432-150-16</p> <p><b>HydroXYzine</b> <b>HYDROCHLORIDE</b> <b>SYRUP, USP</b> <b>10 mg/5 mL</b> <b>Alcohol 0.5%</b></p> <p>DO NOT USE IF INNER FOIL SEAL PRINTED “SEALED FOR YOUR PROTECTION” IS BROKEN OR MISSING.</p> <p><b>BULK CONTAINER —</b> <b>NOT FOR HOUSEHOLD USE</b></p> <p><b>Rx Only</b></p> <p><b>NET: 1 Pint (473 mL)</b></p>	<p>hydrochloride are usually mild and transitory in nature. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Wockhardt USA, LLC. at 1-800-445-4290.</p> <p><b>Skin and Appendages:</b> Oral hydroxyzine hydrochloride is associated with fixed drug eruptions in postmarketing reports.</p> <p><b>Anticholinergic:</b> Dry mouth.</p> <p><b>Central Nervous System:</b> Drowsiness is usually transitory and may disappear in a few days of continued therapy or upon reduction of the dose. Involuntary motor activity including rare instances of tremor and convulsions have been reported, usually with doses considerably higher than those recommended. Clinically significant respiratory depression has not been reported at recommended doses.</p> <p><b>OVERDOSAGE</b> The most common manifestation of hydroxyzine overdosage is hypersedation. As in the management of overdosage with any drug, it should be borne in mind that multiple agents may have been taken.</p> <p>If vomiting has not occurred spontaneously, it should be induced. Immediate gastric lavage is also recommended. General supportive care, including frequent monitoring of the vital signs and close observation of the patient, is indicated. Hypotension, though unlikely, may be controlled with intravenous fluids and levaterenol, or metaraminol. Do not use epinephrine as hydroxyzine counteracts its pressor action.</p> <p>There is no specific antidote. It is doubtful that hemodialysis would be of any value in the treatment of overdosage with hydroxyzine. However, if other agents such as barbiturates have been ingested concomitantly, hemodialysis may be indicated. There is no practical method to quantitate hydroxyzine in body fluids or tissue after its ingestion or administration.</p> <p><b>DOSE AND ADMINISTRATION</b> For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states</p>	<p>in which anxiety is manifested: in adults, 50 to 100 mg q.i.d.; children under 6 years, 50 mg daily in divided doses and over 6 years, 50 to 100 mg daily in divided doses.</p> <p>For use in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus: in adults, 25 mg t.i.d. or q.i.d.; children under 6 years, 50 mg daily in divided doses and over 6 years, 50 to 100 mg daily in divided doses.</p> <p>As a sedative when used as a premedication and following general anesthesia: 50 to 100 mg in adults, and 0.6 mg/kg in children.</p> <p>When treatment is initiated by the intramuscular route of administration, subsequent doses may be administered orally.</p> <p>As with all medications, the dosage should be adjusted according to the patient's response to therapy.</p> <p><b>HOW SUPPLIED</b> Hydroxyzine Hydrochloride Syrup, USP 10 mg per 5 mL (teaspoonful) is a colorless, peppermint-flavored syrup, supplied in 4 fl oz (118 mL) and Pint (473 mL) bottles.</p> <p><b>RECOMMENDED STORAGE</b> <b>Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].</b></p> <p><b>PROTECT FROM FREEZING</b> <b>PROTECT FROM LIGHT</b> Dispense in a tight, light-resistant container as defined in the USP, with child-resistant closure.</p> <p><b>Rx Only</b> Product No.: 8150 <b>Manufactured For:</b> <b>Wockhardt USA, LLC.</b> <b>Parsippany, NJ 07054</b> <b>Manufactured By:</b> <b>Morton Grove Pharmaceuticals, Inc.</b> <b>Morton Grove, IL 60053</b> A50-8150-16 <span style="float: right;">REV. 04-14</span></p>
---	---	--

<b>MGP PROOFING</b>	
Signature 1 _____	Date _____
Signature 2 _____	Date _____
<input type="checkbox"/> MAKE CHANGES; SEND NEW PROOFS	
<input type="checkbox"/> OK TO PRINT APPROVED BY _____ <small>(Signature Required)</small>	

Face

p4

p5

<p><b>HYDROXYZINE HYDROCHLORIDE SYRUP, USP</b> <b>10 mg/5 mL</b> <b>Rx only</b></p> <p><b>DESCRIPTION</b> Hydroxyzine hydrochloride is designated chemically as (±)-2-[2-[4-(p-Chloro-cc-phenylbenzyl)-1-piperazinyl]ethoxy]ethanol dihydrochloride. Its structural formula is as follows:</p>  <p><math>C_{21}H_{27}ClN_2O_2 \cdot 2HCl</math> <span style="float: right;">M.W. 447.83</span></p> <p><b>Inactive Ingredients</b> for Hydroxyzine Hydrochloride Syrup are: alcohol 0.5%; liquid sugar; methylparaben; peppermint oil; propylene glycol; propylparaben; purified water and spearmint oil. <b>It may also contain</b> citric acid anhydrous or sodium citrate dihydrate for pH adjustment. The pH range is between 2.0 and 4.3.</p> <p><b>CLINICAL PHARMACOLOGY</b> Hydroxyzine hydrochloride is unrelated chemically to the phenothiazines, reserpine, meprobamate, or the benzodiazepines. Hydroxyzine is not a cortical depressant, but its action may be due to a suppression of activity in certain key regions of the subcortical area of the central nervous system. Primary skeletal muscle relaxation has been demonstrated experimentally. Bronchodilator activity, and antihistaminic and analgesic effects have been demonstrated experimentally and confirmed clinically. An antiemetic effect, both by the apomorphine test and the veriloid test, has been demonstrated. Pharmacological and clinical studies indicate that hydroxyzine in therapeutic dosage does not increase gastric secretion or acidity and in most cases has mild antisecretory activity. Hydroxyzine is rapidly absorbed from</p>	<p>the gastrointestinal tract and its clinical effects are usually noted within 15 to 30 minutes after oral administration.</p> <p><b>INDICATIONS AND USAGE</b> For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested.</p> <p>Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus.</p> <p>As a sedative when used as premedication and following general anesthesia, <b>hydroxyzine may potentiate meperidine and barbiturates</b>, so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent.</p> <p>The effectiveness of hydroxyzine as an anti-anxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient.</p> <p><b>CONTRAINDICATIONS</b> Oral hydroxyzine hydrochloride is contraindicated in patients with known hypersensitivity to hydroxyzine hydrochloride products, and in patients with known hypersensitivity to cetirizine hydrochloride or levocetirizine hydrochloride.</p> <p>Hydroxyzine, when administered to the pregnant mouse, rat, and rabbit, induced fetal abnormalities in the rat and mouse at doses substantially above the human therapeutic range. Clinical data in human beings are inadequate to establish safety in early pregnancy. Until such data are available, hydroxyzine is contraindicated in early pregnancy.</p> <p>Hydroxyzine is contraindicated for patients who have shown a previous hypersensitivity to it.</p> <p><b>WARNINGS</b></p>	<p><b>Keep out of the reach of children.</b></p> <p><b>Nursing Mothers:</b> It is not known whether this drug is excreted in human milk. Since many drugs are so excreted, hydroxyzine should not be given to nursing mothers.</p> <p><b>PRECAUTIONS</b> THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES. Therefore, when central nervous system depressants are administered concomitantly with hydroxyzine, their dosage should be reduced.</p> <p>Since drowsiness may occur with use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery while taking hydroxyzine. Patients should be advised against the simultaneous use of other CNS depressant drugs, and cautioned that the effect of alcohol may be increased.</p> <p><b>Geriatric Use:</b> A determination has not been made whether controlled clinical studies of hydroxyzine included sufficient numbers of subjects aged 65 and over to define a difference in response from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.</p> <p>The extent of renal excretion of hydroxyzine has not been determined. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selections.</p> <p>Sedating drugs may cause confusion and oversedation in the elderly; elderly patients generally should be started on low doses of hydroxyzine and observed closely.</p> <p><b>ADVERSE REACTIONS</b> Side effects reported with the administration of hydroxyzine</p>
--	---	---

p1

p2

p3



This color proof or PDF is a representation of the colors and will not reflect the final press output.

<b>DISPOSITION</b>	<b>DISPOSITION APPROVED BY</b> _____
It is important that OLD computer files/disks, art, plates and negs be destroyed to avoid production of obsolete items. Please approve the above procedure when approving the revised art.	
	<b>DATE</b> _____

**THIS IS A \*REVISED FILE**

**\*REVISED FILES REQUIRE A "DISPOSITION APPROVAL" SIGNATURE. VariMed CAN NOT RELEASE THE "APPROVED" "REVISED" ART WITH OUT THIS SIGNATURE.**

▲ PULL SLOWLY TO OPEN

**MGP**

NDC 60432-150-16

**HydroXYzine  
HYDROCHLORIDE  
SYRUP, USP  
10 mg/5 mL  
Alcohol 0.5%**

DO NOT USE IF INNER FOIL SEAL PRINTED "SEALED FOR YOUR PROTECTION" IS BROKEN OR MISSING.

**BULK CONTAINER —  
NOT FOR HOUSEHOLD USE**

Rx Only

**NET: 1 Pint (473 mL)**

**MGP**

NDC 60432-150-16

**HydroXYzine  
HYDROCHLORIDE  
SYRUP, USP  
10 mg/5 mL  
Alcohol 0.5%**

DO NOT USE IF INNER FOIL SEAL PRINTED "SEALED FOR YOUR PROTECTION" IS BROKEN OR MISSING.

**BULK CONTAINER —  
NOT FOR HOUSEHOLD USE**

Rx Only

**NET: 1 Pint (473 mL)**

**FPO --Imprint Area-- FPO**

Each 5 mL (teaspoonful) contains:  
HydroXYzine Hydrochloride, USP . . . . . 10 mg  
Alcohol . . . . . 0.5%

**Slight loss unavoidable**  
USUAL DOSAGE: See package insert.

**WARNING: KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN.**  
In case of accidental overdose, seek professional assistance or contact a Poison Control Center immediately.

**RECOMMENDED STORAGE: Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].**

**PROTECT FROM FREEZING**  
**PROTECT FROM LIGHT**

Dispense in a tight, light-resistant container as defined in the USP, with child-resistant closure.  
Manufactured For: Wockhardt USA, LLC.  
Parsippany, NJ 07054  
Manufactured By: Morton Grove Pharmaceuticals, Inc.  
Morton Grove, IL 60053  
ASO-8150-16 REV. 04-14



3 60432-150-16 3

**MGP PROOFING**

Signature 1 \_\_\_\_\_ Date \_\_\_\_\_

Signature 2 \_\_\_\_\_ Date \_\_\_\_\_

**MAKE CHANGES; SEND NEW PROOFS**

---

**OK TO PRINT**  
**APPROVED BY** \_\_\_\_\_  
(Signature Required)

(b) (4)

This color proof or PDF is a representation of the colors and will not reflect the final press output.

**DISPOSITION**

It is important that OLD computer files/disks, art, plates and negs be destroyed to avoid production of obsolete items. Please approve the above procedure when approving the revised art.

**DISPOSITION APPROVED BY** \_\_\_\_\_

**DATE** \_\_\_\_\_

(b) (4)

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

ROBERT L WEST

06/03/2014

Deputy Director, Office of Generic Drugs, for  
Kathleen Uhl, M.D.